Wed.Aug 07, 2024

article thumbnail

Novartis' IgAN ambition takes shape with expanded FDA nod for Fabhalta

Fierce Pharma

The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. | The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line.

FDA 321
article thumbnail

BioMarin keeps but scales down Roctavian gene therapy ops

pharmaphorum

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian but is reining back its ambitions for the business, for now

Pharma 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk pulls its FDA heart failure submission for Wegovy, will reapply early next year

Fierce Pharma

Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025.

FDA 316
article thumbnail

Cigna Distributes Grants to 22 Nonprofits Focused on Youth Mental Health

MedCity News

Cigna is distributing about $3 million to 22 nonprofits addressing youth mental health. Over the next three years, the company is allocating $9 million total. The post Cigna Distributes Grants to 22 Nonprofits Focused on Youth Mental Health appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Amgen's marketing efforts help boost Tepezza sales

Fierce Pharma

Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? | Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? In the second quarter, Tepezza generated $479 million in sales for an increase of 8% year over year and 13% sequentially.

Sales 314
article thumbnail

WebMD’s New Tech Targets Referral Leakage as Providers Continue to Battle Rising Costs

MedCity News

WebMD Ignite recently released new products aimed at helping providers close financial gaps by targeting a specific problem: revenue leakage. The post WebMD’s New Tech Targets Referral Leakage as Providers Continue to Battle Rising Costs appeared first on MedCity News.

115
115

More Trending

article thumbnail

Wegovy slowdown rattles Novo Nordisk investors

pharmaphorum

Weaker sales of obesity drug Wegovy cause a dip in Novo Nordisk's share price, but CEO says volume growth is strong and will accelerate in second half

Sales 111
article thumbnail

After 2023 snub, Amneal clinches approval for extended-release Parkinson's disease med Crexont

Fierce Pharma

As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal has taken home the gold in the U.S. | Late Wednesday, the FDA granted approval to Amneal’s Crexont—formerly known as IPX203—which is an oral, extended-release formulation of the common Parkinson’s disease (PD) drugs carbidopa/levodopa (CD/LD).

FDA 283
article thumbnail

The Critical Imperative for Health Plans to Tackle Late Payment Interest

MedCity News

Health plans can reduce late payment interest by up to 25% year over year by focusing on three critical areas. The post The Critical Imperative for Health Plans to Tackle Late Payment Interest appeared first on MedCity News.

111
111
article thumbnail

England's NICE clears Vertex, CRISPR's Casgevy in beta thalassemia after passing on sickle cell use

Fierce Pharma

On the rocky road to ensuring access to gene therapy Casgevy in the U.K., Vertex and CRISPR Therapeutics are making inroads by securing a thumbs up from England’s National Institute for Health and | The cost-effectiveness regulator recommended government funding for the groundbreaking gene-editing therapy in one of its two approved indications.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos

MedCity News

G1 Therapeutics turned research from the University of North Carolina at Chapel Hill into novel cancer drug Cosela, which is approved in the U.S. and China. Pharmacosmos says its G1 acquisition will enable Cosela to reach more lung cancer patients around the world. The post Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos appeared first on MedCity News.

Patients 111
article thumbnail

With Wegovy supplies back on tap, Novo Nordisk's obesity med doubles US prescriptions from start of year

Fierce Pharma

With supplies of its star obesity med Wegovy now largely unfettered, Novo Nordisk is dialing up its sales expectations for the remainder of the year—and teasing the potential for net price declines | With supplies of its star obesity med Wegovy now largely unfettered, Novo Nordisk is dialing up its sales expectations for the remainder of the year—and teasing the potential for net price declines on the immensely popular GLP-1.

article thumbnail

Pandemic Lesson: How to Move Healthcare From the Emergency Room to the Living Room

MedCity News

As many as 25 percent of all ER visits by older adults come from people with dementia. A better alternative is urgent medical response at home – working with seniors in their own familiar place without the pressures, distractions, or costs of a bustling ER. Or the endless wait times. The post Pandemic Lesson: How to Move Healthcare From the Emergency Room to the Living Room appeared first on MedCity News.

article thumbnail

After sharp declines, Merck KGaA and analysts share optimism about potential CDMO rebound

Fierce Pharma

Despite a rocky start to the year for Merck KGaA’s contract development and manufacturing group, the German company is finding some reason to be optimistic about its recent performance. | After a rocky start to the year, Merck KGaA’s CDMO and process solutions units appear to be nearing a comeback.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

7 Proactive Steps to Improve Customer Loyalty 

Salesforce

When a customer isn’t happy, businesses tend to scramble and try to turn things around. However, reactive marketing is like a Band-Aid. It might stop the immediate hurt or frustration, but it doesn’t fix the underlying problem. Eventually, the wound could be reopened. The way around this is to build customer loyalty with an “always on” marketing strategy.

Marketing 105
article thumbnail

Madrigal's Rezdiffra off to strong start, but 'bumpiness' is coming: analyst

Fierce Pharma

In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. | In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million.

Sales 246
article thumbnail

Levicept says non-opioid drug cuts arthritis pain in phase 2

pharmaphorum

A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with osteoarthritis in a phase 2 trial.Neurotrophin-3 (NT-3) inhibitor LEVI-04 hit all its primary and secondary objectives in the trial, which enrolled 510 patients with moderate-to-severe osteoarthritis of the knee, raising the hope it could become a non-addictive option for patients needing chronic pain relief.

Patients 105
article thumbnail

Pharma Pulse 8/7/24: Struggling AI Startups Look for a Bailout from Big Tech, Strategic Market Access Ensures the Right Treatments at the Right Time & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 104
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

NICE backs osteoporosis drug, but diagnosis is an obstacle

pharmaphorum

Around 14,000 women in England may soon be able to access osteoporosis drug Eladynos from Theramex after NICE backed NHS use

102
102
article thumbnail

The Value in Committing to Conscientious Corporate Stewardship

Pharmaceutical Commerce

Why it is important for organizations to set long-term goals when planning for a sustainable future?

94
article thumbnail

Servier bags FDA okay for glioma drug from $2bn Agios buy

pharmaphorum

FDA approves Servier's IDH 1/2 inhibitor vorasidenib as the first targeted therapy for incurable brain cancer glioma

FDA 97
article thumbnail

Janssen’s psoriasis drug shows promise for childhood diabetes

PharmaTimes

Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK

88
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

What Is the DSCSA?

Pharmaceutical Commerce

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Sr. Director, DSCSA/Serialization Compliance Services, Two Labs, offers a brief overview of the Drug Supply Chain Security Act.

Pharma 64
article thumbnail

MRC and MND Association award ÂŁ3.9m to KCL and UCL for ALS/FTD research

PharmaTimes

Researchers aim to explore and investigate axonal dysfunction in neurodegeneration

Medical 88
article thumbnail

There’s No Such Thing as Too Much Data

PM360

In June 2024, the FDA extended a Cooperative Research and Development Agreement (CRADA) to assess data quality in multicenter clinical trials using statistical modeling and ML. François Torche, Chief Product & Technology Officer & Co-Founder at CluePoints dispels the myth that, at least in RBQM, there is such a thing as too much data, and discusses how advanced data analytics platforms are the key to ensuring every data point has a chance to share its story.

Safety 59
article thumbnail

Addressing industry challenges through flexible, personalized eCOA solutions

Pharmaceutical Technology

eCOA platforms must center the real-world needs of patients, sites, and sponsors to ensure meaningful data capture and trial success.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

AI UPDATE: Generative AI to Have Massive Impact on Search

PM360

Pharma Brands Can Take Steps Now to Prepare Intelligence is changing how we access information and the industry behind it. Since Google’s launch, when people needed to ask a question or find information they jumped to a search engine. While we have come a long way from the original 10 blue links, the search industry has not seen such a watershed moment in its lifespan until now.

article thumbnail

Amgen reports 45.9% decline in net income to $746m in Q2 2024

Pharmaceutical Technology

Amgen has reported a 45.9% decrease in net income to $746m in Q2 2024 compared to $1.3bn in the same period of the previous year.

59
article thumbnail

GLP-1 Agonists Show Promise in Treatment of Neurodegenerative Disorders

Pharmacy Times

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

58
article thumbnail

Data Visualization: A Useful Tool

PM360

How to fully exploit data visualization in clinical trials to ensure all valuable insights are unlocked. Data visualization is a hot topic in clinical trials with its potential to increase efficiency, protect participant safety, and guide informed decision-making to deliver the best chances for trial success. However, data visualization is evolving rapidly and is about far more than just moving from lists and spreadsheets to graphs and charts.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A